This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsuyama, H. Articles by Ekman, P. Search for Related Content PubMed PubMed Citation Articles by Matsuyama, H. Articles by Ekman, P.

Deletions on Chromosome 8p22 May Predict Disease Progression As Well As Pathological Staging in Prostate Cancer¹

Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan [H. M., K. O., S. Y., K. M., K. N.], and Department of Urology, Karolinska Hospital, Stockholm 171-76, Sweden [Y. P., L. H., D. K., U. S. R. B., P. E.]

Purpose: A recent report demonstrated that the deletion of chromosome 8p22 could predict disease progression in stage III (capsular penetrating) prostate cancer. We studied if the status of chromosomal deletions of 8p22 could reflect pathological stage as well as patient prognosis, thereby serving as a diagnostic tool to optimize the treatment strategy in prostate cancer.

Experimental Design: A total of 97 patients (41 Japanese and 56 Swedish) were studied by the fluorescence in situ hybridization technique. Seventy-seven patients (23 pT2, 18 pT3, and 36 pN+ tumors) underwent surgery (radical prostatectomy or lymph node dissection). The specimens were prepared by touch biopsy. From another 20 cases, fine-needle aspiration biopsies were obtained.

Results: 8p22 deletions were detected in 47 (61%) and 11 (55%) specimens of 77 touch biopsies and 20 fine-needle aspiration biopsies, respectively. No significant difference was found in the frequency of 8p22 deletion between different preparations of specimens, as well as between different races (Japanese versus Swedish). The frequency of 8p22 deletion was statistically higher in patients with pT3 or more than in those with pT2 (P < 0.01). Disease progression was evaluated in 57 patients. The Cox proportional hazards model revealed 8p22 deletion to be the strongest parameter to predict disease progression (hazards ratio = 5.75; P = 0.0001).

Conclusions: Studies on chromosomal deletions of 8p22 by fluorescence in situ hybridization technique may serve as a genetic marker to optimize the treatment strategy in patients with prostate cancer to the optimal treatment.

This article has been cited by other articles:

				E. Sunami, M. Shinozaki, C. S. Higano, R. Wollman, T. B. Dorff, S. J. Tucker, S. R. Martinez, F. R. Singer, and D. S.B. Hoon Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients Clin. Chem., March 1, 2009; 55(3): 559 - 567. [Abstract] [Full Text] [PDF]

				W. Xue, A. Krasnitz, R. Lucito, R. Sordella, L. VanAelst, C. Cordon-Cardo, S. Singer, F. Kuehnel, M. Wigler, S. Powers, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma Genes & Dev., June 1, 2008; 22(11): 1439 - 1444. [Abstract] [Full Text] [PDF]

				J.-Z. Pang, L.-X. Qin, N. Ren, Z.-Y. Hei, Q.-H. Ye, W.-D. Jia, B.-S. Sun, G.-L. Lin, D.-Y. Liu, Y.-K. Liu, et al. Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7363 - 7369. [Abstract] [Full Text] [PDF]

				M. Guan, X. Zhou, N. Soulitzis, D. A. Spandidos, and N. C. Popescu Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications Clin. Cancer Res., March 1, 2006; 12(5): 1412 - 1419. [Abstract] [Full Text] [PDF]

				C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]

				R. von Knobloch, L. Konrad, P. J. Barth, H. Brandt, S. Wille, A. Heidenreich, R. Moll, and R. Hofmann Genetic Pathways and New Progression Markers for Prostate Cancer Suggested by Microsatellite Allelotyping Clin. Cancer Res., February 1, 2004; 10(3): 1064 - 1073. [Abstract] [Full Text] [PDF]

				J.-H. Park, J. E. Walls, J. J. Galvez, M. Kim, C. Abate-Shen, M. M. Shen, and R. D. Cardiff Prostatic Intraepithelial Neoplasia in Genetically Engineered Mice Am. J. Pathol., August 1, 2002; 161(2): 727 - 735. [Abstract] [Full Text] [PDF]